Dharti Proteins reported a net loss of ₹14.28 lakh for the quarter ended June 30, 2026, widening from a loss of ₹4.60 lakh in the corresponding period of the previous year. The company recorded nil revenue from operations during Q1FY27, while total expenses increased to ₹14.34 lakh from ₹6.89 lakh in the prior year quarter. The unaudited standalone financial results were approved by the Board of Directors at a meeting held on July 15, 2026.

The company’s other income declined significantly to ₹0.06 lakh in Q1FY27 from ₹2.29 lakh in the quarter ended June 30, 2025. Employee benefits expense stood at ₹2.64 lakh, while other expenses accounted for ₹11.70 lakh during the reported quarter. There were no exceptional or extraordinary items recorded in Q1FY27, unlike the preceding quarter ended March 31, 2026, which saw exceptional items of ₹39.17 lakh.

Financial Performance

The table below summarizes the key financial metrics for Dharti Proteins for the quarter ended June 30, 2026, compared with the previous year.

Auditor and Regulatory Compliance

The statutory auditors, M/s. N. S. Nanavati & Co., Chartered Accountants, performed a limited review of the financial results in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The auditors issued an unmodified opinion on the unaudited standalone financial results. The Audit Committee reviewed the results prior to Board approval.

Earnings per share (EPS) for the quarter ended June 30, 2026, was reported at (₹2.86) on both a basic and diluted basis. The paid-up equity share capital remained at ₹50.00 lakh with a face value of ₹10 per share. The financial results were prepared in compliance with the Indian Accounting Standards (Ind AS) under Section 133 of the Companies Act, 2013.

In compliance with Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published the standalone unaudited financial results in "Free Express, Gujarat" (English) and "Lokmitra" (Gujarati) on July 16, 2026.

Dharti Proteins Ltd has secured listing approval from BSE Limited for 5,00,000 equity shares of Rs. 10 each, following a resolution plan sanctioned by the National Company Law Tribunal (NCLT), Ahmedabad Bench. The approval, conveyed via letter DCS/AMAL/NB/IBC/52/2026-27 dated June 16, 2026, paves the way for the shares to be traded on the exchange. The company is currently executing corporate actions with NSDL and CDSL and will shortly apply for trading permission.

The share allotment was executed pursuant to the NCLT order dated November 18, 2025. The distribution includes 25,000 equity shares allotted due to a reduction of capital. The remaining 4,75,000 equity shares were allotted on a preferential basis, with 4,25,000 shares going to the Successful Resolution Applicant (SRA), identified as the Promoter or Promoter Group, and 50,000 shares allocated to a Secured Financial Creditor.

Allotment Breakdown

The following table details the distribution of the 5,00,000 equity shares approved for listing:

To facilitate trading, Dharti Proteins must submit several documents to the exchange, including ISIN activation letters, an auditor's certificate for book value determination, and confirmation letters from depositories regarding the credit of shares. Additionally, the company is required to provide pre- and post-arrangement shareholding patterns and lock-in confirmations as per SEBI (ICDR) Regulations, 2018.

The intimation was submitted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dharti Proteins Limited, formerly known as Devika Proteins Limited, is headquartered in Ahmedabad, Gujarat.